The Prevalence of Side Effects of Sinopharm COVID-19 Vaccine: An Experience From Pakistan.

Introduction Vaccination for coronavirus disease 2019 (COVID-19) helps develop protective immunity against COVID-19 without experiencing potentially severe illness. Many vaccines are used worldwide, but there is little data on the efficacy and side effects of the Sinopharm vaccine. Therefore, this study aimed to investigate the reported adverse effects of the Sinopharm vaccine among participants. Methods This prospective cross-sectional study was conducted in multiple hospitals in Karachi, Pakistan. The study was eight months, from April 1, 2022, to November 30, 2022. A total of 600 participants who gave informed consent and had received their first and second doses of the Sinopharm vaccine were included in the study. As hypertension and diabetes mellitus (DM) are common prevalent conditions in our population, the duration of DM and hypertension were documented as means and standard deviations apart from age, height, and weight. Side effects of the Sinopharm vaccine were reported as frequencies and percentages. Results The study findings showed that out of 600 participants, 376 (62.7%) were males and 224 (37.3%) were females; their mean age was 42.79±14.44 years. Among them, 130 (21.7%) had hypertension, and 138 (23.0%) had DM. All participants received the Sinopharm vaccine. Fever was the most frequently reported adverse effect following the first dose of the Sinopharm vaccine in 308 (51.3% of participants), followed by burning at the injection site in 244 (40.7% of participants) and pain at the injection site in 228 (38.0% of participants). Following the second dose of the Sinopharm vaccine, fever was the most frequently reported side effect in 254 (42.3%) participants, followed by pain at the injection site in 236 (39.5%) participants and burning at the site of injection in 210 (35.0%) participants. Moreover, joint pain in 194 (32.3%), shortness of breath in 170 (28.3%), swelling of glands in 168 (28.0%), chest pain in 164 (27.3%), and muscle pain were reported by 140 (23.3%) participants. The level of satisfaction showed that the majority of the participants, 334 (55.7%), were satisfied, 132 (22.0%) were very satisfied with their vaccination, and only 12 (2.0%) were dissatisfied. Conclusion This study concluded that fever was the most frequent side effect after both doses of the Sinopharm vaccine. Pain and burning at the injection site and joint pain were among the other common side effects reported by most participants. The Sinopharm COVID-19 vaccine had mild, predictable, and non-life-threatening side effects after the first and second doses.

Investigation of COVID-19 Vaccine Acceptance and Early Side Effects of COVID-19 Vaccine in Hemodialysis Patients

Objective: We aimed to evaluate the acceptance of the COVID-19 vaccines and the frequency of side effects in hemodialysis patients. Methods: Patients receiving regular hemodialysis treatment were included in the study. Patients were asked for their opinions about whether they should have the COVID-19 vaccine. It was recorded which side effects were seen in patients who had received the COVID-19 vaccine. Results: Ninety-two patients who received hemodialysis treatment were evaluated, and 92.4% of them expressed a positive opinion about the COVID-19 vaccine. Patients who were not vaccinated for COVID-19 reported that they were not vaccinated because they thought the vaccine was ineffective. The mean age of patients who did not want to be vaccinated for COVID-19 was lower (P = .019). Among patients who experienced side effects after at least one of the vaccines, and patients who experienced side effects after the first dose of the COVID-19 vaccine, the frequency of side effects was significantly higher in those who received the Pfizer-BioNTech vaccine (P = .001 and P = .001). When the first dose, second dose, and 2 doses of the COVID-19 vaccine were evaluated together, the relationship between increasing age and the decrease in the frequency of side effects was significant (P = .00, P = .001, and P = .015). Conclusion: The vaccination rate against COVID-19 was high in hemodialysis patients, and the most common reason for vaccine opposition was the thought that the vaccine was ineffective. In addition, the frequency of side effects was lower, it was observed that the side effects decreased with age, and the side effects were more frequent in mRNA. © 2023 Turkish Society of Nephrology. All rights reserved.

Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages 5-17.

COVID-19 vaccination of U.S. children lags behind adult vaccination, but remains critical in mitigating the pandemic. Using a subset of a nationally representative survey, this study examined factors contributing to parental uptake of COVID-19 vaccine for children ages 12-17 and 5-11, stratified by parental COVID-19 vaccination status. Among vaccinated parents, uptake was higher for 12-17-year-olds (78.6%) than 5-11-year-olds (50.7%); only two unvaccinated parents vaccinated their children. Child influenza vaccination was predictive of uptake for both age groups, while side effect concerns remained significant only for younger children. Although parents were more likely to involve adolescents in vaccine decision-making than younger children, this was not predictive of vaccine uptake. These results highlight the importance of addressing the unique and shared concerns parents have regarding COVID-19 vaccination for children of varying ages. Future work should further explore adolescent/child perspectives of involvement in COVID-19 vaccination decision-making to support developmentally appropriate involvement.

Effectiveness of Nutritional Supplements for Attenuating the Side Effects of SARS-CoV-2 Vaccines.

Supplementation is known to enhance the immune response and reduce infection. Therefore, the association between immune nutrients and vaccine side effects needs to be investigated. Our aim was to analyze the relationship between vaccination side effects and supplement intake among the Italian population. The study included a questionnaire asking for personal data, anthropometric information, COVID-19 infection and immunity response, and COVID-19 vaccination and supplementation. The survey was conducted from 8 February to 15 June 2022. In the study, 776 respondents were included, aged between 18 and 86 (71.3% females). We observed a statistically significant correlation between supplement consumption and side effects at the end of the vaccination cycle (p = 0.000), which was also confirmed by logistic regression (p = 0.02). Significant associations were observed between supplement intake and side effects of diarrhea and nausea at the end of the vaccination cycle (p = 0.001; p = 0.04, respectively). Significant associations were observed between side effects and omega-3 and mineral supplementation at the start of the vaccination cycle (p = 0.02; p = 0.001, respectively), and between side effects and vitamin supplementation at the end of the vaccination cycle (p = 0.005). In conclusion, our study shows a positive impact of supplementation on vaccination response, increasing host immune defenses, and reducing side effects.

Monitoring Mentions of COVID-19 Vaccine Side Effects on Japanese and Indonesian Twitter: Infodemiological Study.

Background: The year 2021 was marked by vaccinations against COVID-19, which spurred wider discussion among the general population, with some in favor and some against vaccination. Twitter, a popular social media platform, was instrumental in providing information about the COVID-19 vaccine and has been effective in observing public reactions. We focused on tweets from Japan and Indonesia, 2 countries with a large Twitter-using population, where concerns about side effects were consistently stated as a strong reason for vaccine hesitancy. Objective: This study aimed to investigate how Twitter was used to report vaccine-related side effects and to compare the mentions of these side effects from 2 messenger RNA (mRNA) vaccine types developed by Pfizer and Moderna, in Japan and Indonesia. Methods: We obtained tweet data from Twitter using Japanese and Indonesian keywords related to COVID-19 vaccines and their side effects from January 1, 2021, to December 31, 2021. We then removed users with a high frequency of tweets and merged the tweets from multiple users as a single sentence to focus on user-level analysis, resulting in a total of 214,165 users (Japan) and 12,289 users (Indonesia). Then, we filtered the data to select tweets mentioning Pfizer or Moderna only and removed tweets mentioning both. We compared the side effect counts to the public reports released by Pfizer and Moderna. Afterward, logistic regression models were used to compare the side effects for the Pfizer and Moderna vaccines for each country. Results: We observed some differences in the ratio of side effects between the public reports and tweets. Specifically, fever was mentioned much more frequently in tweets than would be expected based on the public reports. We also observed differences in side effects reported between Pfizer and Moderna vaccines from Japan and Indonesia, with more side effects reported for the Pfizer vaccine in Japanese tweets and more side effects with the Moderna vaccine reported in Indonesian tweets. Conclusions: We note the possible consequences of vaccine side effect surveillance on Twitter and information dissemination, in that fever appears to be over-represented. This could be due to fever possibly having a higher severity or measurability, and further implications are discussed.

Safety of COVID-19 Vaccines;Frequency of Side Effects and Association with Sociodemographic Characteristics among Medical Students

ABSTRACT Objective: To find out the side effects of vaccines of COVID-19 and its association with sociodemographic factors among students of medical colleges of Rawalpindi. Study Design: Cross sectional analytic study. Place and Duration of Study: A cross-sectional analytical study was carried out from May to Aug 2022 among medical students of three Medical Colleges (AMC, FUMC, RMC) in Rawalpindi Pakistan. Methodology: There were 200 participants that were conveniently selected with the Rao soft sample size calculator. A validated questionnaire was used to collect data. SPSS (v:26) was used to analyze the data. Chi square analysis was used to assess the relationship between side effects and demographic characteristics and a p-value of 0.05 was taken as significant. Results: Majority of the participants were male 126(63%) and unmarried 182(94%). The mean age of the participants was 20 years (SD=1.4). Almost all were vaccinated 197(98.5%) with two doses 195(97.5%). The side effects after the first dose were more profound as compared to the second dose, like normal pain 133(66.5%), tenderness at injection sit e 69(34.5%), fever 65(32.5%) and fatigue 80(40%). Muscular pains were also documented to be pronounced after the administration of first dose 58(29%). Association analysis showed significant association between first dose side effects, normal pain(p=0.001), tenderness (p=0.004), redness (p=0.02) and fatigue (p=0.02) with gender variable. Whereas age and degree socio demographic variables reported significant association with first dose side effects, normal pain (p=0.04) and muscle pain (p=0.01), respectively. Conclusion: It was conclusive that adverse effects were more common and more severe after the first dose than after the second. The most frequent side effect was normal pain at the injection site, found more frequently in men, with muscular pain being noticeably worse after the first dosage and surprisingly minimal following the second dose of the COVID-19 vaccination.

Safety of COVID-19 Vaccines;Frequency of Side Effects and Association with Sociodemographic Characteristics among Medical Students

Objective: To find out the side effects of vaccines of COVID-19 and its association with sociodemographic factors among students of medical colleges of Rawalpindi. Study Design: Cross sectional analytic study. Place and Duration of Study: A cross-sectional analytical study was carried out from May to Aug 2022 among medical students of three Medical Colleges (AMC, FUMC, RMC) in Rawalpindi Pakistan. Methodology: There were 200 participants that were conveniently selected with the Rao soft sample size calculator. A validated questionnaire was used to collect data. SPSS (v:26) was used to analyze the data. Chi square analysis was used to assess the relationship between side effects and demographic characteristics and a p-value of 0.05 was taken as significant. Results: Majority of the participants were male 126(63%) and unmarried 182(94%). The mean age of the participants was 20 years (SD=1.4). Almost all were vaccinated 197(98.5%) with two doses 195(97.5%). The side effects after the first dose were more profound as compared to the second dose, like normal pain 133(66.5%), tenderness at injection site 69(34.5%), fever 65(32.5%) and fatigue 80(40%). Muscular pains were also documented to be pronounced after the administration of first dose 58(29%). Association analysis showed significant association between first dose side effects, normal pain(p=0.001), tenderness (p=0.004), redness (p=0.02) and fatigue (p=0.02) with gender variable. Whereas age and degree socio demographic variables reported significant association with first dose side effects, normal pain (p=0.04) and muscle pain (p=0.01), respectively. Conclusion: It was conclusive that adverse effects were more common and more severe after the first dose than after the second. The most frequent side effect was normal pain at the injection site, found more frequently in men, with muscular pain being noticeably worse after the first dosage and surprisingly minimal following the second dose of the COVID-19 vaccination. © 2022, Army Medical College. All rights reserved.

Association between COVID-19 vaccine side effects and history of nutritional supplement intake and body mass index (BMI): a retrospective study

PurposeAs the development and vaccination of the COVID 19 vaccine is accelerating worldwide, it is important to investigate the ways to improve immunity and immune responses to vaccines. This study aims to investigate the association between history of nutritional supplements intake and body mass index (BMI) in the severity of COVID-19 vaccine side effects after vaccination.Design/methodology/approachA total of 465 vaccinated participants with the Sinopharm vaccine (females and males in the 18–65 age range) participated in the study. Anthropometric measurements were taken on the first visit. In addition, nutrient supplement history and demographic information were collected. Moreover, the participants' phone numbers were collected and they were contacted. Participants were asked to report if they experienced systemic (whole-body) and/or local side effects after vaccination, in the following eight days. Then, participants were grouped into four categories: no symptoms (n = 232), mild symptoms (n = 121), moderate symptoms (n = 55) and severe symptoms (n = 57).FindingsThere was a significant difference between the consumption of nutritional supplements by different groups of participants in the last six months (considering the severity of the symptoms) (p < 0.001). The odds ratio (OR) and 95% confidence intervals (CI) for the incidence of side effects from the COVID-19 vaccine increased in the Q3 of BMI (range 22.94–26.34) in Modes 2 and 3: [OR: 1.85, (95% CI: 1.14– 3.00), p-for trend = 0.08] and [OR: 1.89, (95% CI: 1.16– 3.09), p-for trend = 0.09] based on logistic regression models.Originality/valueIn this study, the history of nutrient supplement intake affects the severity of side effects after the vaccination with COVID-19. Furthermore, based on logistic regression models, side effects were more prevalent in the BMI range 22.9–26.3 when compared to BMI < 20.2 so further study is necessary.

Adverse Events of BNT162b2 (Pfizer) COVID-19 Vaccine in Children Aged 12 to 17 Years in Thailand

Background: The coronavirus disease 2019 (COVID-19) has been sabotaging the world over the last two years and vaccine is one of the key solutions. However, the concerns over its side effects can cause vaccine refusal, subsequently affecting many countries' education system recovery plans. Objective(s): To actively evaluate adverse effects and their severity following COVID-19 immunization among schoolchildren aged 12 to 17 years, to support parents' decision-making. Material(s) and Method(s): The present study was an observational study whereby a Google-form survey on Pfizer COVID-19 vaccine adverse effects (CVAE) was responded between January and April 2022 by 537 participants. Descriptive statistics were used to analyze basic characteristics. Chi-square tests were performed for comparative analyses between junior (aged 12 to 15 years) versus senior (aged 16 to 17 years) high school students, and McNemar's test for the first dose versus second dose groups analysis with a significance level set at p-value less than 0.05. Result(s): At least one CVAE was reported in 93.85% of the included participants, albeit mostly mild. The most common symptom as a local event was tenderness at the puncture site (82.50%), whereas systemic events were predominated by myalgia (74.67%). The second dose was associated with increased frequency and severity of adverse effects compared to the first dose (p<0.001). The older age group had significantly more side effects compared to the younger group (p<0.05). Conclusion(s): The high incidence of CVAEs in schoolchildren was predominated by mild symptoms, with the second dose and older group associated with increased frequency of symptoms. The predominance of mild symptoms found in the present study may help reduce the concerns of parents over CVAEs, ultimately accelerating vaccine coverage in the children group, which is still a gap in vaccine administration.Copyright © 2023 JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND.

Moderna COVID-19 Vaccine: A New Player in Vaccine-Induced Thrombosis Without Thrombocytopenia.

This is a case of a 31-year-old male with no past medical history who developed extensive pulmonary embolism (PE) and deep venous thrombosis (DVT) three days after receiving the second dose of the Moderna vaccine. The patient presented with left calf swelling and mild shortness of breath, with no fever or hemodynamic instability. Doppler ultrasound of the left lower extremity showed thrombus in the common femoral, superior, mid-, and distal femoral, popliteal, and posterior tibial veins. Chest CT angiography (CTA) visualized extensive pulmonary emboli in the bilateral main pulmonary, lobar, and segmental arteries. Comprehensive hypercoagulable workup was unrevealing. The leading diagnosis was postulated as vaccine-induced thrombosis (VIT). Due to the diagnosis of bilateral sub-massive PE, the patient was initiated on enoxaparin and continued on direct-acting oral anticoagulation for at least one year. Our report showcases a plausible link between the Moderna vaccine and thrombosis due to the extensive and unprovoked nature of DVT/PE in this patient with a negative hypercoagulable workup. Although the mechanisms behind the messenger ribonucleic acid (mRNA) and double-stranded deoxyribonucleic acid (dsDNA) vaccines vary, the possibility of vaccine-induced thrombosis (VIT) after the Moderna vaccine is highly probable. Vaccine-induced thrombosis should be considered in a patient presenting with unprovoked thrombosis after the Moderna COVID-19 vaccine, and further research needs to be conducted to ascertain the correlation. However, these findings should not dissuade the use of the Moderna vaccine given its proven benefits.

Frequency of COVID-19 vaccine side effects and its associated factors among the vaccinated population of Pakistan: A cross-sectional study.

Background: Coronavirus disease 2019 (COVID-19) vaccine side effects have an important role in the hesitancy of the general population toward vaccine administration. Therefore, this study was conducted to document the COVID-19 vaccine side effects in our population. Materials and Methods: An online survey-based, cross-sectional study was carried out from September 1, 2021, to October 1, 2021, to document the side effects of the COVID-19 vaccine among the general public. The questionnaire included participants' sociodemographic data, type of vaccine, comorbidities, previous COVID-19 infection, and assessment of side effects reported by them. Results: The majority of the participants were <20 years of age (62.2%), females (74.9%), belonged to the educational sector (58.1%), residents of Sindh (65.7%), and were previously unaffected by COVID-19 infection (73.3%). Sinovac (38.7%) followed by Sinopharm (30.4%) and Moderna (18.4%) were administered more frequently. Commonly reported side effects were injection site pain (82%), myalgia (55%), headache (46%), fatigue/malaise (45%), and fever (41%). Vaccine side effects were more likely to be reported with the first dose as compared to the second dose. On regression analysis, factors associated with occurrence of side effects included younger age (odds ratio [OR]: 6.000 [2.065-17.431], p < 0.001), female gender (OR: 2.373 [1.146-4.914], p = 0.020), marital status (OR: 0.217 [0.085-0.556], p < 0.001), graduate level of education (OR: 0.353 [0.153-0.816], p = 0.015), and occupation being either retired, freelancers, or social workers (OR: 0.310 [0.106-0.909]), p = 0.033). Previous infection with COVID-19 (p = 0.458) and comorbidities were found unrelated (p = 0.707) to the occurrence of side effects. Conclusion: The overall prevalence of local side effects was quite higher than the systemic ones. Further large-scale studies on vaccine safety are required to strengthen public confidence in the vaccination drive.

Covid-19 Vaccine Side Effects and Its Associated Factors Among Healthcare Workers at Dessie Hospital, Ethiopia.

Background: Vaccines are a powerful choice to stop disease outbreaks, including covid-19. However, people are hesitant to take vaccinations due to uncertainty about side effects. So, this study aimed to assess covid-19 vaccine side-effect and its associated factors among healthcare workers in Dessie comprehensive specialized hospital, in Ethiopia. Methods: An institution-based cross-sectional study was conducted at Dessie Comprehensive and Specialized Hospital among 351 vaccinated healthcare workers from April 25 to May 25, 2021. Self-administrated questionnaires were used by consented health workers. Variance inflation factor (VIF) was used to assess the multicollinearity of independent variables. Bivariable and multivariable binary logistic regression were used to identify significant factors of vaccine side effects. The adjusted odds ratio (AOR) with a 95% confidence interval (CI) was reported as the effect size. Statistical significance was considered at p-value <0.05. Results: Overall, of vaccinated healthcare workers, 56.98% (95% CI, 50.86-61.26%) experienced at least one side effect. The majority of the side effects were fever (44.44%), headache (39.03%), fatigue (27.35%), injection site pain (25.93%), and nausea (24.22%). Healthcare workers with (≥10 years) of work experience (AOR: 3.74, 95% CI, 1.32-10.59), Hesitancy to take the first dose of the Covid-19 vaccine (AOR: 3.01, 95% CI, 1.82-4.99), underlying chronic disease (AOR: 14.41, 95% CI, (5.07-40.92)), being on antihypertensive medication (AOR: 0.15; 95% CI (0.02-0.93)), and unsafe perception of vaccine safety (AOR:3.50; 95% CI, 1.43-8.57) were independent factors of Covax vaccine side effect development. Conclusion: Overall, common vaccine side effects were identified in healthcare workers who have taken the Covax vaccine. Healthcare workers with (≥10 years) of work experience, Hesitancy to take the first dose, unsafe perception of vaccine safety, and underlined chronic disease were predictors of vaccine side effect occurrence. So, providing vaccine-related information to the community to be vaccinated is mandatory to reduce hesitancy and flaws regarding vaccine safety.

Multimorbidity and Its Effect on Self-Reported Adverse Effects Following COVID-19 Vaccination.

Introduction The coronavirus disease 2019 (COVID-19) vaccination has been suggested for those with comorbidities, although there are concerns regarding the vaccine's safety. This study aimed to compare the severity and incidence of post-vaccination side effects in people with and without comorbidities. Another aim of this study was also to look for the effect of multimorbidity on adverse events. Methods This observational study was conducted from November 2021 to February 2022. Data were collected from all over Pakistan using a self-administered online questionnaire that inquired about the subject's demographic, clinical, and COVID-19 vaccination profiles. Data analysis was done by using SPSS software version 22.0. (Chicago, IL, IBM Corp.). Results A total of 421 participants were included in the study, and 31.4% of individuals had underlying comorbidity. The overall mean age was 33 years (range: 13-85 years). This study included recipients of all major types of COVID-19 vaccines being used in Pakistan. Only 67.4% of the subjects had only underlying comorbidity, and hypertension was the most common one out of all comorbidities. Participants with comorbidities were not at a greater risk to produce vaccine-related adverse events when compared to those with no comorbidities. Comorbidity was also found to be statistically non-significant to the severity of the side effects. Only one subject with comorbidity produced a side effect and required hospitalization. Multimorbidity was not associated with a greater incidence of side effects. Multimorbidity was not significantly linked with the severity of the adverse effects, except muscle pain (p<0.05) and breathlessness (p<0.05). Conclusion It can be concluded that comorbidities do not affect the COVID-19 vaccine's reactogenicity but studies on an extensive scale should be conducted regarding individuals with multiple pre-existing comorbidities.

Overview of COVID-19 Vaccine and Investigation of Side Effects in Patients Over 65 Years of Age with Chronic Kidney Disease

Objective: The entire population should be vaccinated to prevent the spread of Coronavirus disease-2019 (COVID-19). In this study, we aimed to evaluate the acceptance of the COVID-19 vaccine and the frequency of side effects in patients over 65 years of age with chronic renal failure. Materials and Methods: Patients with chronic renal failure over the age of 65 who applied to the nephrology outpatient clinic between 14.03.2021 and 15.04.2021 were included. Demographic characteristics, comorbidities, whether they were vaccinated, and post-vaccination symptoms were recorded. Results: In our study, 112 patients with chronic renal failure were evaluated. 94% of the patients (105/12) reported a positive opinion about the vaccine. The most common cause of COVID-19 vaccine opposition was related to vaccine side effects (54%). Of the patients included in the study, 89 were vaccinated with CoronaVac. Side effects were seen in 23% of patients after at least one dose of CoronaVac. The most common side effects were uncontrolled blood pressure and pain at the injection site. In patients reporting adverse events after at least one dose of CoronaVac and 1st dose of vaccine;coronary vascular diseases (CVD) was significantly higher (p=0.012, p=0.001), patients receiving hemodialysis treatment had fewer adverse events (p=0.005, p=0.032), and injection site pain was more common in female patients (p=0.023, p=0.023). The most common adverse event after the 2nd dose was uncontrolled blood pressure and was significantly higher in female patients (p=0.023, p=0.001). Conclusion: Although the rate of vaccination against COVID-19 is high in individuals over 65 years of age with chronic kidney disease, the most common reason for vaccine opposition was vaccine side effects. In addition, although the frequency of side effects was lower in our study population, uncontrolled blood pressure was observed differently and it was observed that the presence of cardiovascular disease increased the frequency of side effects. © Copyright 2022 by the Academic Geriatrics Society / European Journal of Geriatrics and Gerontology published by Galenos Publishing House.

Comparison Between ResNet 16 and Inception V4 Network for COVID-19 Prediction

COVID-19 claimed 5 million lives worldwide so far, and the count is continuing. It also affected socio-economic life of almost everybody in the world. Due to COVID-19, mortality and morbidity are continuing, and it is necessary to find new methods and techniques to contain the infection. Every government is trying hard to implement a new strategy to minimize the spread of the virus. COVID-19 infection occurs due to the virus strain SARS-COV-2. Generally, death occurs due to COVID-19 because of suppurative pulmonary infection and subsequent septic shock or multiorgan failure. In the literature, there are some computational techniques which use deep learning models and reported fairly good performance. This paper proposes a new deep learning architecture inception v4 to automatically detect COVID-19 using the chart X-ray images. The proposed methodology provided improved performance of 98.7 and 94.8% of training and validation accuracy. The developed technology can be used to detect COVID-19 with a high performance;the same may be deployed by the various governments in the detection and the management of COVID-19 in an efficient manner. © 2023, The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

Covid Vaccine Adverse Side-Effects Prediction with Sequence-to-Sequence Model

COVID-19 caused more than 5 million deaths in the world. After lot of efforts and hard work of many scientists, few vaccines are discovered and are approved for use. It is necessary to understand and to evaluate systematically with the potential side effects due to the vaccine itself. This work proposed a sequence-to-sequence learning (Seq2Seq) model to predict the adverse effects due to COVID-19 vaccine. Seq2Seq model is used to convert sequences of one domain to another domain. In this work, a structured data such as Vaccine Adverse Event Reposting System (VAERS) data are used to predict the adverse side effects of COVID-19 vaccination. The data formulated for Seq2Seq model architecture and trying to predict the adverse side effects of vaccination with age and gender attribute as input and obtained the result of 88% as average accuracy using long short-term memory-based (LSTM) deep learning model in adverse effect prediction. © 2023, The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

Reactogenicity of COVID-19 Vaccines in Patients With a History of COVID-19 Infection: A Survey Conducted in Pakistan.

Introduction As coronavirus disease 2019 (COVID-19) immunizations become more common, concerns about their safety and reactogenicity have grown. It is important to assess and analyze the post-vaccination side effects of several COVID-19 vaccines that have been licensed in Pakistan. Methods and results A comparative cross-sectional study was conducted between October 2021 and January 2022 to collect data on the side effects produced by different COVID-19 vaccines. An online survey was conducted to gather data on participants' demographics, clinical profiles, COVID-19 profiles as well as the intensity and side effects of COVID-19 vaccines. Statistical Package for the Social Sciences (SPSS) version 22.0 (IBM Corp., Armonk, NY) was used to analyze the data collected. Out of 421 participants, 63.2% were males, 36.8% of participants received messenger RNA (mRNA) vaccine, 33.2% received viral vector vaccine, 29.9% received inactivated vaccine, and further 71.7% of the total subjects were completely immunized. The majority of the symptoms were mild to moderate in degree. Approximately, 0.7% of the individuals reported experiencing serious adverse effects. Injection site pain (35.9%) was noted to be the most remarkable post-vaccination side effect followed by fever (33.2%) and fatigue (23.1%). Prior COVID-19 infection was not associated with the severity of any COVID-19 vaccine-related side effect (p > 0.05), except dyspnea. Younger participants and the female gender were substantially linked to post-vaccination adverse effects. Conclusion In comparison to viral vector and inactivated vaccines, our data suggest that the mRNA-based vaccination causes more severe adverse effects, and the majority of them were mild to moderate in severity. Participants who had previously contracted COVID-19 were not at a higher risk of developing additional vaccine-related side effects.

From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community.

BACKGROUND: The rapid authorization and widespread rollout of COVID-19 vaccines in the United States demonstrated a need for additional data on vaccine side effects, both to provide insight into the range and severity of side effects that might be expected in medically-diverse populations as well as to inform decision-making and combat vaccine hesitancy going forward. Here we report the results of a survey of 4825 individuals from southcentral Kentucky who received two doses of either the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) vaccine between December 14, 2020 and May 1, 2021. As new versions of the vaccine are rolled-out, local initiatives such as this may offer a means to combat vaccine hesitancy in reference to COVID-19, but are also important as we face new viral threats that will necessitate a rapid vaccine rollout, and to combat a growing public distrust of vaccines in general. METHODS: Individuals that received two doses of either BNT162b2 or mRNA-1273 between December 14, 2020 and May 1, 2021 were sent a survey, created by the research team. Respondents were asked to rate the incidence and severity of 15 potential side effects and two related outcomes following each of their two doses of the vaccine. All statistical analyses were carried out using SYSTAT, version 13. The data were analyzed utilizing a range of statistical tests, including chi-square tests of association, Cohen's h, Kruskal-Wallis test one-way nonparametric ANOVA, least-squares regression, and Wilcoxon signed-ranks test. Significance was assessed using Bonferroni-adjusted criteria within families of tests. RESULTS: In general, the pattern and severity in side effects was similar to both clinical trial data as well as other published studies. Responses to the mRNA-1273 vaccine were more severe than to BNT162b2, though all were generally in the mild to moderate category. Individuals who reported having previously tested positive for COVID-19 reported stronger responses following the first dose of either vaccine relative to COVID-naïve individuals. The reported severity to the COVID-19 vaccine was positively correlated with self-reported responses to other vaccines. CONCLUSIONS: Our findings allow broad-scale estimates of the nature and severity of reactions one might expect following vaccination within a clinically-diverse community, and provide a context for addressing vaccine hesitancy in communities such as ours, where locally-generated data and communication may be more influential than national trends and statistics in convincing individuals to become vaccinated. Further, we argue this community-based approach could be important in the future in three key ways: 1) as new boosters and modified vaccines re-volatilize vaccine hesitancy, 2) as new vaccines receive similar testing and rapid authorization, and 3) to combat vaccine hesitancy in other arenas (e.g., annual vaccines, childhood vaccines).

Successful fractionated undiluted doses of COVID-19 vaccine in five cases of suspected allergic reactions to the first dose.

After a suspected allergic reaction to first dose of mRNA COVID-19 vaccine, given the PEG skin tests negativity and tolerance in vivo to PEG containing drugs, five patients were vaccinated with the second dose of Pfizer-Biontech undergoing a fractional protocol, with antihistamine premedication, without presenting immediate or delayed reactions.

COVID-19 Vaccine-Induced Rapid Progression of Prediabetes to Ketosis-Prone Diabetes Mellitus in an Elderly Male.

Studies show a low progression rate of prediabetes to Type 2 diabetes mellitus (DM) that we commonly seek to reverse, but we don't associate prediabetes as a lead-up to the first presentation of ketosis. We present a prediabetic who, in less than a year, converted to GAD65 antibody-positive diabetes mellitus with a diabetic ketoacidosis presentation. A 69-year-old male presented with three weeks of fatigue, polyuria, polydipsia, abdominal pain, and weight loss. Vital signs and physical exam were normal except for abdominal tenderness and dry oral mucosa. Complete blood count (CBC) was normal; blood glucose was severely elevated with mild corrected hyponatremia; elevated anion gap metabolic acidosis with glucosuria and ketonuria. He received an insulin drip, normal saline, and potassium in the intensive care unit. His anion gap closed overnight and was switched to basal-bolus insulin. Hemoglobin A1c (HbA1c) came out to be higher than expected as compared to last year of low prediabetic value, decreased c-peptide levels, and positive anti-GAD65 antibody. His first abnormal HbA1c was 5.8% a year ago and no autoimmune marker was checked before. He was vaccinated with the messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccine a year ago with an mRNA vaccine booster two months earlier. He was not COVID-19 infected. We discharged him with a basal-bolus insulin regimen. Type I DM passes from autoimmunity-positive normoglycemia to dysglycemia to the symptomatic stage, typically progressing more rapidly in children than in older adults. A new Type I or dysglycemia in Type II DM is increasingly reported after COVID-19 vaccines/infection. Mechanisms could be cytokine-mediated beta-cell damage or autoimmunity after mRNA vaccines or as a part of autoimmune syndrome induced by vaccine adjuvants. This case reports the rapid progression of prediabetes to Type 1 rather than Type 2 DM and highlights the possibility of dysglycemia after COVID-19 vaccines and calls for measures to prevent or early management of these side effects.